Dr. Robert M. Kipperman, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 513
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OK license 19276 · NY license 157221-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morristown Medical Center Morristown, NJ
Medical groups
- Practice Associates Medical Group (1,408 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 513
- Services billed
- 1,245
- Patients’ average age
- 81
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 367 | 138 |
| Established patient office or other outpatient visit, 20-29 minutes | 242 | 176 |
| Established patient office or other outpatient visit, 30-39 minutes | 218 | 209 |
| Replacement of aortic valve through the skin and femoral artery | 122 | 122 |
| Hospital discharge day management, more than 30 minutes | 90 | 90 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 39 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Repair of mitral valve through the skin, initial prosthesis | 26 | 26 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 24 | 24 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 11 companies reported 171 payments worth $6,837 in total to this clinician.
| Medtronic, Inc. | $3,582 |
|---|---|
| Edwards Lifesciences Corporation | $1,548 |
| Abbott Laboratories | $647 |
| Aop Health US, LLC | $510 |
| Shockwave Medical, Inc | $180 |
| Stryker Corporation | $110 |
| Cardiva Medical, Inc. | $72.08 |
| Boston Scientific Corporation | $55.29 |
| Food and Beverage | $6,837 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 3 companies. The companies reported $821,989 in research payments for these studies, mostly to the institutions running them.
- CLASP IIF (2018-07)
Edwards Lifesciences Corporation - CLASP IID 2018-07
Edwards Lifesciences Corporation - CLASP II TR Pivotal, Study No. 2019-07
Edwards Lifesciences Corporation - NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Abbott Laboratories - TRISCEND II Pivotal (2020-05)
Edwards Lifesciences Corporation - Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19
Edwards Lifesciences Corporation - TRISCEND II Pivotal Trial 2020-05 CONTINUED ACCESS STUDY
Edwards Lifesciences Corporation - Edwards PASCAL Transcatheter Valve Repair System in Tricuspid Regurgitation (CLASP TR) Early Feasibility Study
Edwards Lifesciences Corporation - The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (2016-05)
Edwards Lifesciences Corporation - CoreValve SURTAVI
Medtronic, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.